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Staphylococcus aureus infective endocarditis (SaIE) is a severe complication of
S. aureus bacteremia (SAB) occurring in up to 22% of patients. Bacterial genetic
factors and host conditions for SaIE have been intensely studied before; however,
to date no study has focused on predisposing host genetic factors to SaIE. The
present study aimed to identify genetic polymorphisms associated with SaIE by a
Genome-Wide Association Study (GWAS) of 67 patients with definite native valve SaIE
(cases) and 72 matched native valve patients with SAB but without IE (controls). All
patients were enrolled in the VIRSTA cohort (Le Moing et al., 2015) study. Four single
nucleotide polymorphisms (SNPs) located on chromosome 3 were associated with SaIE
(P < 1 × 10−5) without reaching conventional genome-wide significance. For all, the
frequency of the minor allele was lower in cases than in controls, suggesting a protective
effect of the minor allele against SaIE. The same association was observed using an
independent Danish verification cohort of SAB with (n = 57) and without (n = 123) IE.
Ex vivo analysis of aortic valve tissues revealed that SaIE associated SNPs mentioned
above were associated with significantly higher mRNA expression levels of SLC7A14,
a predicted cationic amino acid transporter protein. Taken together, our results suggest
an IE-protective effect of SNPs on chromosome 3 during the course of SAB. The effects
of protective minor alleles may be mediated by increasing expression levels of SLC7A14
in valve tissues. We conclude that occurrence of SaIE may be the combination of a
well-adapted bacterial genotype to a susceptible host.
Keywords: infectious endocarditis, Staphylococcus aureus, GWAS, bacteremia, SLC7A14
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INTRODUCTION
Staphylococcus aureus is the second most frequent pathogen
causing bloodstream infection with an average rate of 25 per
100,000 individuals per year in North America and western
European countries (Laupland, 2013). Infective endocarditis (IE)
is one of the most severe complications of S. aureus bloodstream
infection (SAB) and occurs in 5–22% of SAB cases (del Rio et al.,
2009; Rasmussen et al., 2011). Hence, S. aureus is nowadays the
most prevalent bacterial species responsible for IE in the majority
of developed countries (Murdoch et al., 2009; Duval et al.,
2012; Selton-Suty et al., 2012). Fortunately, IE is still a rare but
severe disease, with a mortality of approximately 20% [10–30%]
during the initial hospitalization phase (Moreillon and Que, 2004;
Murdoch et al., 2009; Hoen and Duval, 2012), and up to 40%
at a 5 year endpoint (Bannay et al., 2011). Therefore, detecting
and identifying the pathogen and potential host determinants of
S. aureus IE (SaIE) in the course of SAB is of major importance
for management and prevention of infectious endocarditis.
Several IE risk factors related to the patients’ characteristics
have been described including male sex (Moreillon and Que,
2004; Erichsen et al., 2016) with no particular explanation, history
of IE, congenital heart disease (especially cyanogen corrected)
(Takeda et al., 2005), or presence of intra-cardiac devices, mainly
prosthetic valves. Regarding host-related factors in the context
of SAB, underlying diseases such as diabetes, HIV infection,
hemodialysis and intravenous drug use have been shown to be
primary SaIE risk factors (Li and Somerville, 1998; Cabell et al.,
2002; Chang et al., 2003; Miro et al., 2005; Gebo et al., 2006;
Habib et al., 2009; Hoen and Duval, 2012). Our group recently
developed and validated a simple score-based prediction rule
to quantify the risk of SaIE within 48 h after SAB diagnosis in
patients with community-acquired (CA) or healthcare-associated
(HA) SAB, using the largest prospective cohort of SAB patients
reported to date (the VIRSTA cohort) (Le Moing et al., 2015;
Tubiana et al., 2016). Note that 30–50% of SaIE occurs without
any obvious involvement of the classical host risk factors,
suggesting that additional host genetic factors may be involved
(Hoen and Duval, 2012; Le Moing et al., 2015).
A variety of research findings suggest that there is a genetic
basis for human susceptibility to S. aureus colonization and/or
infection. Evidences include: (i) genetic polymorphism in various
loci associated with nasal carriage (Emonts et al., 2008; Ruimy
et al., 2010), (ii) higher rates of S. aureus infections in distinct
ethnic populations (Maori and Pacific island people versus
European; Aboriginal Australian versus Australian, American
black versus white American) (Embil et al., 1994; Maguire et al.,
1998; Hill et al., 2001; Klevens et al., 2007; Kallen et al., 2010),
(iii) familial clusters of S. aureus infection (Oestergaard et al.,
2016); (iv) rare genetic conditions associated with susceptibility
to S. aureus (Medvedev and Vogel, 2003; Picard et al., 2003).
More recently, genome-wide association study (GWAS) has
been successful to identify genetic variants robustly associated
with human diseases (Hindorff et al., 2009). Three GWAS
have investigated potential associations between common genetic
variants and human susceptibility to S. aureus infection. Nelson
et al. (2014) compared 361 cases of S. aureus bacteremia to
699 controls (Nelson et al., 2014). Ye et al. (2014) compared
309 infected people to 2952 controls (Ye et al., 2014). In both
cases, no genome-wide significant common variant was found
to be associated with risk of acquiring S. aureus infection.
Most recently, DeLorenze et al. (2016) presented the first
GWAS evidence of human genetic susceptibility to S. aureus
infection (DeLorenze et al., 2016). The investigators genotyped
a Caucasian population of 4,701 cases of S. aureus infection
and 45,344 matched controls. Two imputed SNPs (rs115231074:
p = 1.3 × 10−10 and rs35079132: p = 3.8 × 10−8) achieved
genome-wide significance, and one adjacent SNP was nearly
significant genomewide (rs4321864: p = 8.8 × 10−8). These
polymorphisms were located near HLA-DRA and HLA-DRB1
genes on chromosome 6 in the HLA class II region. These results
were reinforced in an admixture mapping study identifying the
HLA class II region on chromosome 6 associated with SAB
susceptibility (Cyr et al., 2017). However, to date no GWAS has
been conducted for SA-IE in the course of bacteremia.
In the present study, we conducted a GWAS to identify genetic
polymorphisms associated with SaIE in 67 patients presenting
definite native valve IE (cases) and 72 matched patients with SAB
(controls) enrolled in the VIRSTA cohort study. A replication
study was then performed using an independent Danish cohort
of patients with SAB, with and without IE.
MATERIALS AND METHODS
Study Participants of the French VIRSTA
Cohort
Patients were enrolled as part of the French national prospective
multicenter cohort VIRSTA (Le Moing et al., 2015). Briefly,
2,091 patients aged over 18 years and presenting at least one
peripheral blood culture positive for S. aureus were included
from 2009 to 2011. Patients were recruited in eight teaching
hospitals. Among these patients, 221 (11%) had definite IE
according to the modified Duke criteria (Li et al., 2000). To study
differences between IE and bacteremia isolates, this nested case-
control study retained 211 patients with definite native valve
IE and the presence of echocardiographic vegetation as defined
cases. Patients with native cardiac valve meeting the “possible”
or “excluded IE” definition, without any argument for IE using
Transesophageal Echocardiography (TEE) during a 3-month
follow-up period were defined as controls. Cases and controls
were matched according to age, sex and the SAB setting of
acquisition [healthcare-related (HA) either nosocomial or non-
nosocomial vs. community-acquired (CA)]. All patients provided
written informed consent.
Comparison of the characteristics of the patients enrolled in
the present case control genetic study versus the entire cohort of
the VIRSTA study was realized using Chi-square or Fisher’s exact
test for qualitative variables and Student’s t-test for quantitative
variables with SAS9.3.
The French national ethics committee “Comité de Protection
des Personnes SudMéditerrannée IV” approved the study. The
VIRSTA study is registered in the European Clinical Trials
Database (EUDRACT) (number: 2008-A00680-55).
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DNA Extraction and Genotyping
DNA was extracted from blood samples using AGOWA
DNA isolation kits (LGC) according to the manufacturer’s
protocols and genotyped on the Illumina HumanOmni Exp-12v1
BeadChip array at the Human Genomics Facility (HuGeF1) at
Erasmus University Medical Center, Rotterdam, The Netherlands
(Prof. Dr. André Uitterlinden), according to the manufacturer’s
protocols.
A genotyping report was produced in GenomeStudio V2011.1.
Low quality SNPs were removed based on the Illumina GenCall
(<0.1), call rate lower than 97%, Hardy–Weinberg equilibrium
deviations with p < 7 × 10−8, minor allele frequencies (MAF)
smaller than 0.01 or being monomorphic loci. Low quality
samples were removed based on a SNP call rate <95%, sex
discrepancies and genetic background outliers using Eigenstrat
with HapMap subjects as internal controls (Price et al., 2006).
Quality controls were performed in R 3.4.2 statistical software
and PLINK, an open-source whole genome association analysis
toolset (Purcell et al., 2007). Association between genotypes
and IE was evaluated using chi-square tests implemented in
PLINK. The genome-wide significant p-value cut-off was set at an
established standard (p-value < 5× 10−8) (Pe’er et al., 2008). We
set the level of “suggestive” significance at a p-value lower or equal
to 1 × 10−5. The linkage disequilibrium (LD) plot for SNPs on
chromosome 3 was produced with Haploview 4.2 (Barrett et al.,
2005).
Minor Allele Frequencies of rs2287489
and rs4955730 in Control and Reference
Populations
To assess the frequency of alleles of interest in the general
population which were of similar geographic origin as
the VIRSTA cohort, we used a cohort of subjects not
infected with S. aureus: the COFRASA cohort consisting
of 486 patients with degenerative aortic valve stenosis
(Guauque-Olarte et al., 2015; Nguyen et al., 2015). Inclusion
criteria were, at least, mild aortic stenosis (mean pressure
gradient ≥ 10 mm Hg) and aortic valve structural changes
(thickening/calcification). Exclusion criteria were aortic
valve stenosis due to rheumatic disease or radiotherapy,
ongoing or previous aortic endocarditis, coexisting aortic
regurgitation, other valvular diseases and severe respiratory or
renal insufficiency (creatinine clearance ≤ 30 ml/min). DNA
was extracted from frozen buffy coat using the QIAamp R© DNA
Blood Maxi kit (QIAGEN). Genotyping was performed at the
McGill University and Genome Quebec Innovation Center
using the Illumina HumanOmniExpress-12v1.0 BeadChip.
Quality controls for SNPs and samples were performed as
described above. Analyses were conducted to determine the
minor allele frequencies of rs2287489 and rs4955730. The
allele frequencies of these two SNPs were also compared to
publically available databases including the Exome Aggregation
Consortium (ExAC) and the Genome Aggregation Database
(gnomAD) (Lek et al., 2016), the 1000 Genomes Project
1www.glimdna.org
(1000 Genomes Project Consortium et al., 2015) and the Human
Longevity Inc (HLI) 10,000 genomes (Telenti et al., 2016).
COFRASA participants were enrolled under procedures
approved by the “Comité de Protection de Personnes”,
Hotel Dieu, Paris, France. The procedure is registered in
clinicalTrial.gov number NCT 00338676.
Replication Set: The DANSAB Danish
Cohort
To validate the results obtained with the VIRSTA cohort, analysis
of the top SNPs was carried out using the DANSAB Danish
cohort. The DANSAB cohort is a subset of individuals partaking
in a large continuous study, running since 2009, involving
S. aureus bacteremia patients from six large clinical microbiology
departments (DANSAB study). The patients selected in this study
were defined as patients with S. aureus bacteremia. They were
divided into two groups: (1) a control group (N = 144) with
bacteremia with no secondary infections up to a year after initial
diagnosis of S. aureus bacteremia and (2) a group with definite IE
according to Duke’s criteria (N = 57). All patients were > 18 years
of age and suffered from either CA or HA related infections. Of
these, we were able to obtain genotyping data on 123 controls and
57 IE cases.
Samples were obtained through either collection of blood
cultures with DNA purified from between 5 and 10 mL blood
culture using a Chemagic Star DNA Blood10K kit (Perkin Elmer)
or from the Copenhagen Biobank with DNA purified using the
QiaAMP Blood Midikit (Qiagen, Germany).
The regions encompassing the candidate SNPs, namely
rs2287489 and rs4955730 were amplified by PCR using Gotaq kit
(Promega) and the forward (5′-CAGAGCGGGGGTCTGCTT
AC-3′) and reverse (5′-TTTCGTGGCCAGGCCACCAC-3′)
primers for rs4955730 or forward (5′-CTGGGCTGAGAGAGGG
GGC-3′) and reverse (5′-TTGTACAGCACACCAATGGGA-3′)
primers for rs2287489. Primers were designed on SLC7A14 gene
sequence (accession number NM_020949). The DNA sequences
were obtained by Sanger sequencing and genotypes at both SNPs
were read from the chromatograms.
DANSAB participants were enrolled under procedures
approved by the Danish Regional Ethics Committee (journal
no. H-4-2014-132) and the Danish Data Protection Agency
(GEH2014-053 // I-suite no 03372 and journal no. 2007-58-
0015).
Valve Expression Quantitative Trait Loci
(eQTL)
The functional characterization of SaIE-associated SNPs was
extended to genotype-specific gene expression analysis in
human aortic valves. Tricuspid aortic valves were explanted
from 24 white male patients who underwent aortic valve
replacement for severe calcific aortic valve stenosis at the Institut
Universitaire de Cardiologie et de Pneumologie de Québec
(IUCPQ). Only non-rheumatic aortic valves with the same fibro-
calcific remodeling score were selected (Warren and Yong, 1997).
Patients with other valve diseases, previous cardiac surgery, and
moderate or severe aortic regurgitation were excluded. DNA was
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FIGURE 1 | Flow chart of patient recruitment in the VIRSTA case control study. IE, Infective endocarditis. TEE, Transesophageal echocardiography. TTE,
Transthoracic echocardiography.
extracted from 100 mg of frozen aortic valve tissue digested with
Qiagen’s proteinase K at 56◦C for 16 h, followed by column
purification using QIAamp R© DNA Mini kit (Qiagen). DNA
quality was assessed by UV260/280 nm ratio. DNA concentration
was determined by QuantiTTM PicoGreenTM dsDNA Assay
Kit. Genotyping was performed using the Illumina Infinium
HumanOmni2.5–8 BeadChip. SNPs were excluded based on
Hardy–Weinberg (P < 0.01), minor allele frequency smaller than
0.01 or call rates lower than 0.97. DNA samples were removed
based on completion rate lower than 0.95, sex discrepancies,
duplicates and genetic background. Data from 24 patients and
1,474,616 SNPs passed all these quality controls and were
available for analysis. Total RNA was extracted from 100 mg
of tissue using RNeasy R© Plus Universal Mini Kit (Qiagen).
RNA quality was assessed by the Agilent 2100 Bioanalyzer
system. RNA concentration was determined by UV260 nm.
Gene expression was measured on the Illumina HumanHT-12v4
Expression BeadChip. Samples were removed based on outliers in
pairwise correlation, principal components analysis (PCA), and
hierarchical clustering. After these quality controls, 22 samples
were available for analysis. mRNA expression data were log2
transformed and quantile normalized using the lumi package
in R (Du et al., 2008). Both whole-genome genotyping and
gene expression were performed in a single batch at the McGill
University and Genome Quebec Innovation Center. mRNA
transcripts were selected for valve eQTL analysis if they were
located near the top GWAS SNPs. Association testing between
genotypes and mRNA expression levels was performed in PLINK
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TABLE 1 | Comparison of the characteristics of the patients enrolled in the case control genetic study and in the whole cohort.
Definite Staphylococcus aureus native valve endocarditis SAB patients without IE
Characteristics Cases Whole VIRSTA cohort p Controls Whole VIRSTA cohort p
N 78 106 78 1718
Male n (%) 52 (66) 66 (64) 0.74 52 (66) 1106 (64) 0.80
Mean age (years) 58 61 0.26 58 66 0.0003
Injecting drug use n (%) 12 (15) 18 (17) 0.98 6 (8) 33 (2) 0.006
Immuno-suppression∗ 25 (32) 28 (27) 0.49 19 (24) 652 (38) 0.01
Methicillin resistance 12 (15) 9 (9) 0.17 6 (8) 347 (20) 0.006
Setting of acquisition n (%) 0.67 <0.0001
Community 47 (60) 63 (60) 52 (67) 367 (21)
Healthcare-related 12 (15) 19 (18) 8 (10) 306 (18)
Nosocomial 19 (24) 21 (20) 18 (23) 989 (58)
Severe sepsis 36 (46) 49 (47) 0.93 13 (17) 390 (23) 0.19
Death at week 12 19 (24) 47 (45) 0.003 4 (5) 563 (33) <0.0001
VIRSTA study 2009-2011. ∗Patient was classified as suffering immunodepression if presenting a primary immune deficiency, or a solid cancer, leukemia or lymphoma, or
HIV infection with CD4 cell count < 200/ml, or was treated with corticosteroids or other immunosuppressive therapy. The numbers in brackets represent the percentage
of patients.
FIGURE 2 | Manhattan plot of genome-wide association results for the discovery VIRSTA cohort. The x-axis represents the chromosome number and the y-axis
shows the P-values in – log10 scale. Dot represent SNP. A total of 67 cases and 72 controls are compared. 631,710 SNPs that passed all quality control filters are
presented. As indicated in Table 2, two SNPs on chromosome 3 have the same p-value; these two points overlap in present figure.
using the –assoc command (Wald test). Written informed
consent was obtained from all study participants and the study
was approved by the ethics committee of the IUCPQ.
RESULTS
SNPs Potentially Associated With SaIE
Among the 2,091 patients enrolled in the VIRSTA cohort study
(Le Moing et al., 2015), 156 patients fulfilled the inclusion criteria
for the case control study, gave consent and were genotyped by
SNP microarray (Figure 1). Only patients with native valves were
retained considering that the presence of a prosthetic valve is a
major risk factor as such and that may mask the host genetic
risk factors. Eventually, 78 patients presenting definite IE were
compared to 78 SAB –age, -sex and -origin (healthcare associated
vs. community acquired) matched control patients presenting a
SAB (Figure 1).
Table 1 shows the characteristics of the 78 case-patients
enrolled in the case control study as compared to the 106 patients
with definite native valve SaIE from the whole cohort VIRSTA
study 2009–2011. The only difference between the two groups
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FIGURE 3 | Regional association plot of the SaIE susceptibility locus on chromosome 3. The y axis shows the P-values in –log10 scale for SNPs up- and
downstream of the sentinel SNP (purple dot). The extent of linkage disequilibrium (LD; r2 values) for all SNPs with the sentinel SNP is indicated by colors. The
location of genes is shown at the bottom.
TABLE 2 | Genetic variants suggestively associated with S. aureus infective endocarditis in the GWAS of 67 cases and 72 controls of the discovery VIRSTA cohort.
SNP Chromosome Position on Hg19 A1/A2 A1 in cases A1 in controls OR P-value Position to
SLC7A14 gene
Position to
CLDN11 gene
rs6414536 3 170176173 A/G 0.127 0.361 0.257 6.248e-06 – Intron
rs2287489 3 170178057 A/C 0.127 0.361 0.257 6.248e-06 3′ UTR Intron
rs4955730 3 170179621 G/A 0.112 0.361 0.223 1.212e-06 3′ UTR Intron
rs6769887 3 170172774 G/A 0.082 0.285 0.225 1.496e-05 – Intron
Positions of the 4 SNPs on chromosome 3 and relative to the SLC7A14 and CLDN11 genes are indicated. A1, minor allele; A2, major allele; OR, Odd Ratio. Hg19, human
genome 19.
was the mortality, which was higher in patients who were not
enrolled in the case-control study probably because the severity
of their disease precluded the gathering of the consent for DNA
collection.
Table 1 also shows the characteristics of the 78 control patients
enrolled in the case-control genetic study as compared to the
1,718 patients without SaIE from the whole cohort VIRSTA study
2009–2011. Differences between controls and other patients with
bacteremia without endocarditis were more pronounced and
probably mostly due to the matching of controls with cases which
were mostly community-acquired while patients enrolled in the
VIRSTA cohort comprised a large proportion of healthcare-
related bacteremia. In addition, the presence of a prosthetic valve
was excluded in the case control genetic study.
From the 716,503 SNPs and 156 samples available, a total
of 84,793 SNPs and 17 samples failed quality controls, leaving
631,710 SNPs and 139 participants (67 cases and 72 controls)
for analysis. A Manhattan plot of the GWAS results on SaIE is
presented in Figure 2. The Q–Q plot is shown in Supplementary
Figure 1. No SNPs were significantly associated with SaIE at the
genome-wide level (p-value < 5× 10−8). Four “suggestive” SNPs
(p-value < 1× 10−5) were located on one locus on chromosome
3, near the genes CLDN11 and SLC7A14 (Figure 3). Table 2
shows the minor allele frequencies for cases and controls for these
four three SNPs as well as odd ratios. For these four SNPs, the
frequency of the minor allele was lower in cases than in controls,
suggesting a protective effect of the minor allele against SaIE. The
top three associated SNPs (rs6414536, rs2287489, and rs4955730)
are in high LD (r2 > 0.88). The fourth SNP (rs6769887) located
close to the top 3 associated SNPs and in moderate LD (r2 > 0.56)
had a p-value of 1.5 × 10−5. A LD plot for all SNPs located near
(±10 kb) rs2287489 and rs6414536 is presented in Figure 4.
Comparison to Control and Reference
Populations
The frequency of minor alleles in our cases and control
populations was compared to the allele frequencies in a control
population similar in time and space to the discovery VIRSTA
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FIGURE 4 | Linkage disequilibrium plot for SNPs located near (±10 kb) rs2287489 and rs6414536 in the VIRSTA cohort. The white horizontal bar (top) illustrates
SNPs location on a physical scale. LD values (r2) are presented in boxes. Strong LD is defined as an r2 > 0.8 (darkest color). The top four associated SNPs are
framed.
TABLE 3 | Minor allele frequencies of rs2287489 and rs4955730 in cases and controls from VIRSTA compared to COFRASA and reference populations.
SNP A1/A2 A1 in 67 VIRSTA cases A1 in 72 VIRSTA controls A1 in 426 COFRASA patients A1 in European reference populations∗
rs2287489 A/C 0.127 0.361 0.245 0.24–0.26
rs4955730 G/A 0.112 0.361 0.242 0.24–0.25
A1, minor allele; A2, major allele. ∗(1000 Genomes Project Consortium et al., 2015; Lek et al., 2016; Telenti et al., 2016).
cohort population. For this purpose, we used the COFRASA
cohort involving 486 French patients with degenerative aortic
valve stenosis (Guauque-Olarte et al., 2015; Nguyen et al., 2015).
The frequencies of minor alleles for the top two SNPs (rs2287489
and rs4955730, rs6414536 was dropped as it is in perfect LD
with rs2287489) were 0.24 in the COFRASA population, which
is consistent with previously published studies of reference
populations (1000 Genomes Project Consortium et al., 2015; Lek
et al., 2016; Telenti et al., 2016). In our population of cases,
the frequency of the minor alleles is much lower (0.13 and
0.11 for the two SNPs respectively) than the general population.
Conversely, the frequency of the minor alleles is higher in
our population of controls (0.36 for both SNPs) compared to
COFRASA and reference populations (Table 3). These results are
however consistent with the hypothesis of a protective effect of
the minor allele against SaIE.
Replication Using an Independent
Cohort (DANSAB)
The two GWAS top hits on chromosome 3 were then analyzed
in an independent cohort of Danish patients presenting either
a non-complicated bacteremia (controls) or SaIE (cases). We
TABLE 4 | Association analysis of two top SNPs on chromosome 3 and
infection-induced endocarditis in an independent case-control series of patients
with S. aureus endocarditis: the Danish DANSAB cohort.
SNP A1/A2 A1 in 57 SaEI
Cases
A1 in 123
controls
OR P-value
rs2287489 A/C 0.2946 0.3208 0.8843 0.6215
rs4955730 G/A 0.2797 0.3171 0.8362 0.468
A1, minor allele; A2, major allele; OR, Odd Ratio.
genotyped the top two SaIE-associated SNPs (rs2287489 and
rs4955730) in DANSAB. Although the results are not statistically
significant, the minor alleles were also underrepresented in the
cases compared to the controls, suggesting a protective effect as
observed in the GWAS of the French VIRSTA cases and controls
(Table 4). The effect sizes were smaller than those observed in the
VIRSTA cohort.
Impact of SaIE-Associated SNPs on
Gene Expression
Valve eQTL analyses were performed to evaluate whether
the top GWAS SNPs were associated with mRNA expression
Frontiers in Microbiology | www.frontiersin.org 7 April 2018 | Volume 9 | Article 640
fmicb-09-00640 April 3, 2018 Time: 13:50 # 8
Moreau et al. GWAS S. aureus Endocarditis
FIGURE 5 | Gene expression levels of the SLC7A14 gene in human aortic
valves according to 3 genotype groups for the SNP rs4955730 (n = 22,
p = 0.0299). The left y-axis represents gene expression levels in the aortic
valves. The x-axis represents the three-genotype groups for the SNP
rs4955730 with the number of subjects in parenthesis. The right y-axis
represents the percent variance (r2) in expression levels explained by the
genotype for this SNP. The G allele, that seems to have a protective effect for
SaIE, is associated with a higher level of gene expression.
levels of nearby genes in human aortic valves. No SNPs
were associated with the expression of CLDN11 (data not
shown). In contrast, significant associations were observed
for SLC7A14. Figure 5 shows result for the valve eQTL
rs4955730-SLC7A14. The protective allele for SaIE (rs4955730-
G) was associated with significantly increased mRNA levels of
SLC7A14 (encoding a trans-membrane protein with putative
amino acid transport function) in aortic valve tissues. These
results suggest that the minor allele for rs4955730 decreases
vulnerability to SaIE through up-regulation of SLC7A14 in valve
tissue.
DISCUSSION
Although numerous risk factors related to the host have been
identified, 30–50% of endocarditis occur in patients without
any known risk factors (Hoen and Duval, 2012; Le Moing
et al., 2015). Both host and bacterial genetic variation may
explain the difference in IE susceptibility. Considering S. aureus,
genetic variation of genes that encode for virulence, antibiotic
resistance and host adaptation, may contribute to the occurrence
of SaIE in the course of bacteremia. By analyzing the S. aureus
isolates from the VIRSTA cohort, we recently demonstrated
that the strains of S. aureus associated with endocarditis were
genotypically distinct from those responsible for uncomplicated
bacteremia (Bouchiat et al., 2015). We showed that the ability of
S. aureus to cause endocarditis in the course of bacteremia was
not linked to one or a few bacterial factors but more likely to
a combination of more subtle genetic markers (Bouchiat et al.,
2015).
To our knowledge, the present study is the first GWAS
examining potential genetic predisposition for localization to the
endocardium in case of S. aureus bacteremia and highlights four
SNPs closely located on chromosome 3 suggestively associated
with SaIE. The frequency of the minor allele was lowered in
SaIE than in bacteremia controls, non-infected French patients
of the COFRASA cohort, and published reference populations
(1000 Genomes Project Consortium et al., 2015; Lek et al.,
2016; Telenti et al., 2016). The protective effect of the two
top SNPs toward the occurrence of SaIE was also observed
in a second independent Danish cohort (DANSAB), however
with noticeable differences in allele frequencies compared to
the VIRSTA cohort. Both cases and controls from DANSAB
displayed a higher frequency of the minor allele than cases
and controls from VIRSTA respectively. This observation may
result from sample bias or to differences at the level of the
population structure among Danish people, which is markedly
homogenous and genetically distinct from the French population
structure (Athanasiadis et al., 2016). Indeed, the main limitation
of the present study is the lack of statistical significance
obtained in the GWAS, a method that is most successfully
conducted using larger sample sizes. However, the fact that the
protective effect of those three SNPs toward the occurrence of
SaIE was observed in two independent cohorts suggests that
the signal we observed is consistent. Larger cohorts will be
needed to confirm our results but such studies will be very
demanding.
The three SNPs are closely located on chromosome 3,
in a region encompassing two genes encoding Claudin 11
and SLC7A14 proteins. Interestingly, in an ex vivo analysis
of valve tissues, we showed that one of these SNPs was
associated with significant up-regulation of SLC7A14, an orphan
membrane-spanning protein (Figure 5). Taken together, our
results suggest that the protective alleles mediate their effects
by increasing the mRNA expression levels of SLC7A14 in valve
tissues.
SLC7A14 (Solute Carrier Family 7, Member 14) is predicted
to encode a glycosylated, cationic amino acid transporter
protein with 14 trans-membrane domains. This gene is
primarily expressed in skin fibroblasts, neural tissue, and
primary endothelial cells, and its protein is predicted to
mediate lysosomal uptake of cationic amino acids. Mutations
in this gene are associated with autosomal recessive retinitis
pigmentosa (Jin et al., 2014). As little is known about the
function of SLC7A14 protein, it is difficult to speculate on
the pathophysiological mechanism linking expression of this
gene to the occurrence of SaIE. However, the valve eQTL
analysis performed in this study provides the first biological
clue about how genetic variants located on chromosome 3
could be associated with SaIE. Additional studies will be
needed to confirm these observations and uncover the detailed
mechanism of how these variants confer predisposition to
endocarditis.
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Previous studies attempted to identify genetic variants
associated with infective endocarditis regardless of the
etiologic agent. Analyzes were made on small cohorts of IE
patients compared to healthy blood donors and targeted a
priori candidates such as genes involved in inflammation.
Polymorphisms in TLR6, IL1B, IL12B, CRP and CALCR genes
but not IL6 and TNF were associated with a decreased risk of
IE (Golovkin et al., 2015; Ponasenko et al., 2017) while SNPs
in IL1B, IL6,TLR2 and TNF genes were associated with IE
(Bustamante et al., 2011; Giannitsioti et al., 2014; Weinstock
et al., 2014) as compared to healthy donors. None of these
SNPs were identified in the present study, perhaps because our
study focused on S. aureus only and our comparator group was
S. aureus bacteremia patients.
CONCLUSION
The transition from uncomplicated S. aureus bacteremia
to infective endocarditis –which remains the most pressing
medical issue- likely results from a complex interplay
between environmental factors, the host and the pathogen.
The occurrence of SaIE may be the combination of a well-
adapted bacterial genotype to a susceptible host, susceptibility
which may be genetically-determined in some cases of native
valve endocarditis.
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